Use of Immune Suppressive Domains as Medicaments
AssigneesSkau Aps, Aarhus Universitet
InventorsShervin BAHRAMI, Mogens RYTTERGÅRD DUCH, Christian KANSTRUP HOLM, Magdalena Janina LASKA
Life of this patent
Estimating the term…
Abstract
The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.
Claims37
1-87. (canceled)
A pharmaceutical composition comprising an immune suppressive domain as an active substance wherein said immune suppressive domain is different from immunosuppressive domains obeying the conditions of:
- i. being from a virus selected among the group consisting of gammaretrovirus, HIV and filovirus;
- ii. being located in the linker between the two heptad repeat structures just N-terminal of the transmembrane domain in a virus fusion protein;
- and
- iii. including the first 22 amino acids located N-terminal to the first cysteine residue of the two well conserved cysteine residues of a virus fusion protein, located between 4 and 6 amino acid residues from one another and further located just N-terminal of the transmembrane spanning domain of the fusion protein.
A pharmaceutical composition comprising an immune suppressive domain cross-linked to at least one additional immunosuppressive peptide.
A pharmaceutical composition comprising an immune suppressive domain connected to at least one additional immunosuppressive peptide to form a dimer.
A pharmaceutical composition comprising one or more immunosuppressive peptides selected from SEQ ID NOS:1 to 287, an additional active substance, and optionally a carrier.
Dependencies are inferred from the claim text.